• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

日本 1982-2021 年新增肾脏替代治疗的出生队列效应。

Birth cohort effects in incident renal replacement therapy in Japan, 1982-2021.

机构信息

Department of Inter-Organ Communication Research, Niigata University Graduate School of Medical and Dental Sciences, 1-757 Asahimachi, Chuo-Ku, Niigata, 951-8510, Japan.

Division of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.

出版信息

Clin Exp Nephrol. 2023 Aug;27(8):707-714. doi: 10.1007/s10157-023-02345-x. Epub 2023 Apr 4.

DOI:10.1007/s10157-023-02345-x
PMID:37014536
Abstract

BACKGROUND

This study aimed to investigate the long-term trends of incident end-stage kidney disease (ESKD) requiring renal replacement therapy (RRT) in Japan using age-period-cohort analysis and evaluated birth cohort effects for incident ESKD requiring RRT.

METHODS

The number of incident RRT patients aged between 20 and 84 years by sex from 1982 to 2021 was extracted from the Japanese Society of Dialysis Therapy registry data. Annual incidence rates of RRT were calculated using census population as denominators, and changes in the incidence rates were evaluated using an age-period-cohort model. The age and survey year period categories generated 20 birth cohorts with 5-year intervals (from 1902-1907 to 1997-2001).

RESULTS

The incidence rates of RRT in both sexes initially rose in the birth cohorts born in the early 1900s, and then decelerated and peaked during 1940-1960s in men and 1930-1940s in women, following a steady decline in both sexes. Compared with the reference 1947-1951 birth cohort, the highest cohort rate ratio was 1.14 (95% CI, 1.04-1.25) in the 1967-1971 birth cohort in men and 1.04 (95% CI, 0.98-1.10) in the 1937-1941 birth cohort in women.

CONCLUSIONS

Significant cohort effects were identified in both sexes, but the peak of RRT was different for each sex. Our findings suggest that men born between 1940 and 1960s and women born between 1930 and 40 s may be important target populations to consider when decreasing incidence rates of RRT among the general Japanese population.

摘要

背景

本研究旨在使用年龄-时期-队列分析方法研究日本终末期肾病(ESKD)需要肾脏替代治疗(RRT)的长期发病趋势,并评估需要 RRT 的新发 ESKD 的出生队列效应。

方法

从日本透析治疗学会登记处的数据中提取了 1982 年至 2021 年间年龄在 20 至 84 岁之间的新发 RRT 患者的人数,按性别划分。使用人口普查人口作为分母计算 RRT 的年发病率,并使用年龄-时期-队列模型评估发病率的变化。年龄和调查年份周期类别生成了 20 个出生队列,间隔 5 年(从 1902-1907 年到 1997-2001 年)。

结果

男女两性的 RRT 发病率最初在 20 世纪初出生的队列中上升,然后在男性中于 1940-1960 年代和女性中于 1930-1940 年代减速并达到峰值,随后在两性中持续下降。与参考的 1947-1951 年出生队列相比,男性中最高队列的比率为 1.14(95%置信区间,1.04-1.25),女性中为 1.04(95%置信区间,0.98-1.10)。

结论

在两性中都发现了显著的队列效应,但 RRT 的高峰期因性别而异。我们的研究结果表明,1940 年代至 60 年代出生的男性和 1930 年代至 40 年代出生的女性可能是降低日本普通人群 RRT 发病率的重要目标人群。

相似文献

1
Birth cohort effects in incident renal replacement therapy in Japan, 1982-2021.日本 1982-2021 年新增肾脏替代治疗的出生队列效应。
Clin Exp Nephrol. 2023 Aug;27(8):707-714. doi: 10.1007/s10157-023-02345-x. Epub 2023 Apr 4.
2
Trends in the incidence of renal replacement therapy by type of primary kidney disease in Japan, 2006-2020.2006 - 2020年日本按原发性肾脏疾病类型划分的肾脏替代治疗发生率趋势
Nephrology (Carlton). 2023 Feb;28(2):119-129. doi: 10.1111/nep.14134. Epub 2022 Dec 8.
3
Trends in the Incidence of Renal Replacement Therapy Due to Rapidly Progressive Glomerulonephritis in Japan, 2006-2021.2006-2021 年日本快速进展性肾小球肾炎导致的肾脏替代治疗发病率趋势。
Intern Med. 2024 Oct 15;63(20):2751-2755. doi: 10.2169/internalmedicine.3343-23. Epub 2024 Mar 4.
4
Secular trends in end-stage kidney disease requiring renal replacement therapy in Japan: Japanese Society of Dialysis Therapy Registry data from 1983 to 2016.日本终末期肾病接受肾脏替代治疗患者的流行趋势:1983 年至 2016 年日本透析治疗登记协会数据。
Nephrology (Carlton). 2020 Feb;25(2):172-178. doi: 10.1111/nep.13595. Epub 2019 May 1.
5
Characteristics and Outcomes of Patients With Systemic Sclerosis (Scleroderma) Requiring Renal Replacement Therapy in Europe: Results From the ERA-EDTA Registry.欧洲接受肾脏替代治疗的系统性硬化症(硬皮病)患者的特征和结局:来自 ERA-EDTA 登记处的结果。
Am J Kidney Dis. 2019 Feb;73(2):184-193. doi: 10.1053/j.ajkd.2018.05.016. Epub 2018 Aug 16.
6
UK Renal Registry 16th annual report: chapter 8 survival and cause of death of UK adult patients on renal replacement therapy in 2012: national and centre-specific analyses.英国肾脏登记处第 16 份年度报告:第 8 章 2012 年英国成年肾脏替代治疗患者的生存和死因:全国和中心特定分析。
Nephron Clin Pract. 2013;125(1-4):139-69. doi: 10.1159/000360027. Epub 2014 Feb 14.
7
UK Renal Registry 13th Annual Report (December 2010): Chapter 6: survival and causes of death of UK adult patients on renal replacement therapy in 2009: national and centre-specific analyses.英国肾脏注册中心第 13 次年度报告(2010 年 12 月):第 6 章:2009 年英国成年接受肾脏替代治疗患者的生存和死亡原因:全国和中心特定分析。
Nephron Clin Pract. 2011;119 Suppl 2:c107-34. doi: 10.1159/000331756. Epub 2011 Aug 26.
8
ESRD from autosomal dominant polycystic kidney disease in the United States, 2001-2010.2001 - 2010年美国常染色体显性多囊肾病导致的终末期肾病
Am J Kidney Dis. 2014 Oct;64(4):592-9. doi: 10.1053/j.ajkd.2014.05.020. Epub 2014 Aug 16.
9
UK Renal Registry 15th annual report: Chapter 5 survival and causes of death of UK adult patients on renal replacement therapy in 2011: national and centre-specific analyses.英国肾脏注册中心第 15 份年度报告:第 5 章 2011 年英国成年肾脏替代治疗患者的生存和死亡原因:全国和中心特定分析。
Nephron Clin Pract. 2013;123 Suppl 1:93-123. doi: 10.1159/000353324. Epub 2013 Jun 10.
10
Lifetime risk of renal replacement therapy in Europe: a population-based study using data from the ERA-EDTA Registry.欧洲接受肾脏替代治疗的终生风险:基于人群的研究,使用 ERA-EDTA 登记处的数据。
Nephrol Dial Transplant. 2017 Feb 1;32(2):348-355. doi: 10.1093/ndt/gfw392.

引用本文的文献

1
Public Unawareness of Renal Function: A Questionnaire Survey at a Health Promotion Seminar.公众对肾功能的认知不足:在一次健康促进研讨会上的问卷调查
J Clin Med. 2025 Jan 21;14(3):664. doi: 10.3390/jcm14030664.

本文引用的文献

1
Trends in the incidence of renal replacement therapy by type of primary kidney disease in Japan, 2006-2020.2006 - 2020年日本按原发性肾脏疾病类型划分的肾脏替代治疗发生率趋势
Nephrology (Carlton). 2023 Feb;28(2):119-129. doi: 10.1111/nep.14134. Epub 2022 Dec 8.
2
CKD Care Programs and Incident Kidney Failure: A Study of a National Disease Management Program in Taiwan.慢性肾脏病护理项目与新发肾衰竭:台湾一项全国性疾病管理项目的研究
Kidney Med. 2022 May 21;4(7):100485. doi: 10.1016/j.xkme.2022.100485. eCollection 2022 Jul.
3
Secular trends in end-stage kidney disease requiring renal replacement therapy in Japan: Japanese Society of Dialysis Therapy Registry data from 1983 to 2016.
日本终末期肾病接受肾脏替代治疗患者的流行趋势:1983 年至 2016 年日本透析治疗登记协会数据。
Nephrology (Carlton). 2020 Feb;25(2):172-178. doi: 10.1111/nep.13595. Epub 2019 May 1.
4
An Overview of Regular Dialysis Treatment in Japan (As of 31 December 2013).日本常规透析治疗概述(截至2013年12月31日)
Ther Apher Dial. 2015 Dec;19(6):540-74. doi: 10.1111/1744-9987.12378.
5
Anticipated increase in the number of patients who require dialysis treatment among the aging population of Japan.预计日本老龄人口中需要透析治疗的患者数量将会增加。
Ther Apher Dial. 2015 Jun;19(3):201-6. doi: 10.1111/1744-9987.12266. Epub 2014 Dec 29.
6
An overview of regular dialysis treatment in Japan (as of 31 December 2012).日本常规透析治疗概况(截至2012年12月31日)。
Ther Apher Dial. 2014 Dec;18(6):535-602. doi: 10.1111/1744-9987.12281.
7
An overview of regular dialysis treatment in Japan (as of 31 December 2010).日本常规透析治疗概况(截至2010年12月31日)。
Ther Apher Dial. 2012 Dec;16(6):483-521. doi: 10.1111/j.1744-9987.2012.01143.x.
8
Use of Japanese Society for Dialysis Therapy dialysis tables to compare the local and national incidence of dialysis.使用日本透析治疗学会的透析数据表来比较当地和全国的透析发病率。
Ther Apher Dial. 2012 Feb;16(1):63-7. doi: 10.1111/j.1744-9987.2011.01030.x.
9
Overview of regular dialysis treatment in Japan (as of 31 December 2009).日本常规透析治疗概况(截至2009年12月31日)。
Ther Apher Dial. 2012 Feb;16(1):11-53. doi: 10.1111/j.1744-9987.2011.01050.x.
10
Overview of regular dialysis treatment in Japan (as of 31 December 2008).日本定期透析治疗概况(截至2008年12月31日)。
Ther Apher Dial. 2010 Dec;14(6):505-40. doi: 10.1111/j.1744-9987.2010.00893.x.